OPTHEA LIMITED - Announcements

0.00%

60.0¢

Market Cap $820.7M

Healthcare Biotechnology

Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The... Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).More

MEMPHASYS LIMITED

Many are concerned about global falling birthrates. This diverse stock has solutions. Here, then, one can’t afford to miss perusing what ASX-listed fertility tech healthcare smallcap Memphasys Ltd (ASX:MEM) can offer the world.

Announcements

Filter Results

All Price Sensitive Only

OPT	Opthea presents at Oppenheimer's 32nd Healthcare Conference		11/03/22	147.62KB	Share
OPT	Change in substantial holding		09/03/22	334.51KB	Share
OPT	Change in substantial holding		08/03/22	90.12KB	Share
OPT	S&P DJI Announces March 2022 Quarterly Rebalance	PRICE SENSITIVE	04/03/22	175.5KB	Share
OPT	Opthea appoints Dr.Joel Naor M.D as Chief Medical Officer		03/03/22	112.48KB	Share
OPT	Change in substantial holding		03/03/22	77.82KB	Share
OPT	Opthea Half Year Report and Accounts	PRICE SENSITIVE	28/02/22	1.16MB	Share
OPT	Change in substantial holding		22/02/22	320.37KB	Share
OPT	Change in substantial holding		21/02/22	345.74KB	Share
OPT	Becoming a substantial holder		18/02/22	222.8KB	Share
OPT	Change in substantial holding		16/02/22	344.13KB	Share
OPT	Angiogenesis 2022 -Prof Cheung presentation of PCV data	PRICE SENSITIVE	14/02/22	680.37KB	Share
OPT	Opthea data for OPT-302 in patients with PVC as presented	PRICE SENSITIVE	14/02/22	182.15KB	Share
OPT	Opthea present at SVB Leerink Global Healthcare Conference		11/02/22	93.69KB	Share
OPT	Opthea presents at the Angiogenesis 2022 Conference		10/02/22	94.31KB	Share
OPT	Change in substantial holding		09/02/22	307.68KB	Share
OPT	Change in substantial holding		07/02/22	310.78KB	Share
OPT	Change in substantial holding		04/02/22	331.46KB	Share
OPT	Change in substantial holding		03/02/22	344.72KB	Share
OPT	Opthea announces establishment of ATM Equity Program	PRICE SENSITIVE	02/02/22	150.66KB	Share
OPT	Form F-3 Registration Statement	PRICE SENSITIVE	02/02/22	876.99KB	Share
OPT	Becoming a substantial holder		31/01/22	799.29KB	Share
OPT	Ceasing to be a substantial holder		28/01/22	191.43KB	Share
OPT	Becoming a substantial holder		27/01/22	787.88KB	Share
OPT	Ceasing to be a substantial holder		25/01/22	194.63KB	Share
OPT	Opthea Receives A$6.6m R&D Tax Incentive	PRICE SENSITIVE	25/01/22	182.04KB	Share
OPT	Becoming a substantial holder		24/01/22	791.44KB	Share
OPT	Ceasing to be a substantial holder		17/01/22	54.17KB	Share
OPT	Change in substantial holding		17/01/22	1.02MB	Share
OPT	Becoming a substantial holder		14/01/22	808.62KB	Share
OPT	Opthea to present at H.C. Wainwright BIOCONNECT conference		05/01/22	125.9KB	Share
OPT	Opthea appoints CCO to lead Commercialization of OPT-302		04/01/22	130.93KB	Share
OPT	Ceasing to be a substantial holder		23/12/21	67.22KB	Share
OPT	Becoming a substantial holder		16/12/21	924.96KB	Share
OPT	Ceasing to be a substantial holder		14/12/21	213.55KB	Share
OPT	Appendix 2A		14/12/21	273.22KB	Share
OPT	Cleansing Notice		14/12/21	211.45KB	Share
OPT	Change in substantial holding		10/12/21	506.16KB	Share
OPT	Notification regarding unquoted securities - OPT		11/11/21	25.38KB	Share
OPT	Change of Director's Interest Notice-MB		11/11/21	237.3KB	Share
OPT	Notification regarding unquoted securities - OPT		11/11/21	26.8KB	Share
OPT	Change of Director's Interest Notice -JH		10/11/21	235.11KB	Share
OPT	Change of Director's Interest Notice -JR		10/11/21	235.19KB	Share
OPT	Notification regarding unquoted securities - OPT		10/11/21	26.48KB	Share
OPT	Change in substantial holding		03/11/21	70.35KB	Share
OPT	Change in substantial holding		02/11/21	343.62KB	Share
OPT	Change in substantial holding		27/10/21	262.09KB	Share
OPT	Appendix 2A		27/10/21	271.62KB	Share
OPT	Cleansing Notice		27/10/21	211.64KB	Share
OPT	Opthea Granted Chinese Patent Covering OPT-302	PRICE SENSITIVE	27/10/21	87.94KB	Share
OPT	Change in substantial holding		22/10/21	315.38KB	Share
OPT	Becoming a substantial holder		21/10/21	977.07KB	Share
OPT	Cleansing Notice update		21/10/21	254.52KB	Share
OPT	Appendix 2A Update		21/10/21	280.02KB	Share
OPT	Cleansing Notice		21/10/21	211.65KB	Share
OPT	Appendix 2A		21/10/21	280.02KB	Share
OPT	Opthea opens patient enrollment in the Asia-Pacifi Region	PRICE SENSITIVE	20/10/21	132.58KB	Share
OPT	Results of Meeting		19/10/21	200.7KB	Share
OPT	Opthea Corporate Presentation - October 2021	PRICE SENSITIVE	19/10/21	1.93MB	Share
OPT	Opthea Chairman's Address to the 2021 Annual General Meeting	PRICE SENSITIVE	19/10/21	201.98KB	Share
OPT	Ceasing to be a substantial holder		11/10/21	246.1KB	Share
OPT	Opthea's Phase 3 open for patient recruitment in Europe	PRICE SENSITIVE	05/10/21	186.17KB	Share
OPT	Change in substantial holding		01/10/21	333.63KB	Share
OPT	Ceasing to be a substantial holder		24/09/21	82.28KB	Share
OPT	Becoming a substantial holder		21/09/21	204.37KB	Share
OPT	Addendum to Notice of Meeting		21/09/21	273.88KB	Share
OPT	Ceasing to be a substantial holder		16/09/21	90.09KB	Share
OPT	Notice of Annual General Meeting and Proxy Form		14/09/21	591.18KB	Share
OPT	Opthea Appendix 4G Corporate Governance Statement amended		06/09/21	625.05KB	Share
OPT	Opthea to present at September Investor Conferences		03/09/21	126.83KB	Share
OPT	Opthea Appendix 4G Corporate Governance Statement		30/08/21	693.95KB	Share
OPT	Opthea reports Fiscal Year 2021 Results and Highlights	PRICE SENSITIVE	30/08/21	147.59KB	Share
OPT	Opthea Appendix 4E and Annual Report	PRICE SENSITIVE	30/08/21	2.17MB	Share
OPT	Becoming a substantial holder		27/08/21	866.02KB	Share
OPT	Becoming a substantial holder		25/08/21	195.5KB	Share
OPT	Ceasing to be a substantial holder		25/08/21	199.41KB	Share
OPT	Ceasing to be a substantial holder		24/08/21	115.04KB	Share
OPT	Becoming a substantial holder		24/08/21	813.37KB	Share
OPT	Ceasing to be a substantial holder		19/08/21	218.2KB	Share
OPT	Becoming a substantial holder		12/08/21	797.9KB	Share
OPT	Opthea to present at H.C Wainwright Ophthalmology Conference		11/08/21	124.83KB	Share
OPT	Opthea expands Phase 3 for OPT-302 into Canada		10/08/21	184.91KB	Share
OPT	Ceasing to be a substantial holder		03/08/21	402.32KB	Share
OPT	Opthea's OPT-302 Granted Fast-Track for wet AMD	PRICE SENSITIVE	06/07/21	166.94KB	Share
OPT	Change in substantial holding		23/06/21	590.1KB	Share
OPT	Change in substantial holding		22/06/21	90.51KB	Share
OPT	Cleansing Notice		22/06/21	235.42KB	Share
OPT	Application for quotation of securities - OPT		22/06/21	24.64KB	Share
OPT	Change in substantial holding		22/06/21	868.53KB	Share
OPT	Change in substantial holding		21/06/21	311.77KB	Share
OPT	Proposed issue of securities - OPT		21/06/21	24.29KB	Share
OPT	Opthea Appoints Company Secretary and VP of Finance		15/06/21	83.57KB	Share
OPT	Initial Director's Interest Notice-JH		07/06/21	201.33KB	Share
OPT	Initial Director's Interest Notice-JR		07/06/21	201.39KB	Share
OPT	Director Appointment/Resignation		02/06/21	205.32KB	Share
OPT	Change in substantial holding		25/05/21	792.07KB	Share
OPT	Becoming a substantial holder		28/04/21	202.59KB	Share
OPT	Opthea Company Secretary Resignation		06/04/21	85.84KB	Share
OPT	Opthea Receives FDA Waiver for Pediatric Study Plan	PRICE SENSITIVE	31/03/21	159.31KB	Share
OPT	Change in substantial holding		26/03/21	1.09MB	Share

OPT Opthea presents at Oppenheimer's 32nd Healthcare Conference
11/03/22		147.62KB	Share
OPT Change in substantial holding
09/03/22		334.51KB	Share
OPT Change in substantial holding
08/03/22		90.12KB	Share
OPT S&P DJI Announces March 2022 Quarterly Rebalance
04/03/22	PRICE SENSITIVE	175.5KB	Share
OPT Opthea appoints Dr.Joel Naor M.D as Chief Medical Officer
03/03/22		112.48KB	Share
OPT Change in substantial holding
03/03/22		77.82KB	Share
OPT Opthea Half Year Report and Accounts
28/02/22	PRICE SENSITIVE	1.16MB	Share
OPT Change in substantial holding
22/02/22		320.37KB	Share
OPT Change in substantial holding
21/02/22		345.74KB	Share
OPT Becoming a substantial holder
18/02/22		222.8KB	Share
OPT Change in substantial holding
16/02/22		344.13KB	Share
OPT Angiogenesis 2022 -Prof Cheung presentation of PCV data
14/02/22	PRICE SENSITIVE	680.37KB	Share
OPT Opthea data for OPT-302 in patients with PVC as presented
14/02/22	PRICE SENSITIVE	182.15KB	Share
OPT Opthea present at SVB Leerink Global Healthcare Conference
11/02/22		93.69KB	Share
OPT Opthea presents at the Angiogenesis 2022 Conference
10/02/22		94.31KB	Share
OPT Change in substantial holding
09/02/22		307.68KB	Share
OPT Change in substantial holding
07/02/22		310.78KB	Share
OPT Change in substantial holding
04/02/22		331.46KB	Share
OPT Change in substantial holding
03/02/22		344.72KB	Share
OPT Opthea announces establishment of ATM Equity Program
02/02/22	PRICE SENSITIVE	150.66KB	Share
OPT Form F-3 Registration Statement
02/02/22	PRICE SENSITIVE	876.99KB	Share
OPT Becoming a substantial holder
31/01/22		799.29KB	Share
OPT Ceasing to be a substantial holder
28/01/22		191.43KB	Share
OPT Becoming a substantial holder
27/01/22		787.88KB	Share
OPT Ceasing to be a substantial holder
25/01/22		194.63KB	Share
OPT Opthea Receives A$6.6m R&D Tax Incentive
25/01/22	PRICE SENSITIVE	182.04KB	Share
OPT Becoming a substantial holder
24/01/22		791.44KB	Share
OPT Ceasing to be a substantial holder
17/01/22		54.17KB	Share
OPT Change in substantial holding
17/01/22		1.02MB	Share
OPT Becoming a substantial holder
14/01/22		808.62KB	Share
OPT Opthea to present at H.C. Wainwright BIOCONNECT conference
05/01/22		125.9KB	Share
OPT Opthea appoints CCO to lead Commercialization of OPT-302
04/01/22		130.93KB	Share
OPT Ceasing to be a substantial holder
23/12/21		67.22KB	Share
OPT Becoming a substantial holder
16/12/21		924.96KB	Share
OPT Ceasing to be a substantial holder
14/12/21		213.55KB	Share
OPT Appendix 2A
14/12/21		273.22KB	Share
OPT Cleansing Notice
14/12/21		211.45KB	Share
OPT Change in substantial holding
10/12/21		506.16KB	Share
OPT Notification regarding unquoted securities - OPT
11/11/21		25.38KB	Share
OPT Change of Director's Interest Notice-MB
11/11/21		237.3KB	Share
OPT Notification regarding unquoted securities - OPT
11/11/21		26.8KB	Share
OPT Change of Director's Interest Notice -JH
10/11/21		235.11KB	Share
OPT Change of Director's Interest Notice -JR
10/11/21		235.19KB	Share
OPT Notification regarding unquoted securities - OPT
10/11/21		26.48KB	Share
OPT Change in substantial holding
03/11/21		70.35KB	Share
OPT Change in substantial holding
02/11/21		343.62KB	Share
OPT Change in substantial holding
27/10/21		262.09KB	Share
OPT Appendix 2A
27/10/21		271.62KB	Share
OPT Cleansing Notice
27/10/21		211.64KB	Share
OPT Opthea Granted Chinese Patent Covering OPT-302
27/10/21	PRICE SENSITIVE	87.94KB	Share
OPT Change in substantial holding
22/10/21		315.38KB	Share
OPT Becoming a substantial holder
21/10/21		977.07KB	Share
OPT Cleansing Notice update
21/10/21		254.52KB	Share
OPT Appendix 2A Update
21/10/21		280.02KB	Share
OPT Cleansing Notice
21/10/21		211.65KB	Share
OPT Appendix 2A
21/10/21		280.02KB	Share
OPT Opthea opens patient enrollment in the Asia-Pacifi Region
20/10/21	PRICE SENSITIVE	132.58KB	Share
OPT Results of Meeting
19/10/21		200.7KB	Share
OPT Opthea Corporate Presentation - October 2021
19/10/21	PRICE SENSITIVE	1.93MB	Share
OPT Opthea Chairman's Address to the 2021 Annual General Meeting
19/10/21	PRICE SENSITIVE	201.98KB	Share
OPT Ceasing to be a substantial holder
11/10/21		246.1KB	Share
OPT Opthea's Phase 3 open for patient recruitment in Europe
05/10/21	PRICE SENSITIVE	186.17KB	Share
OPT Change in substantial holding
01/10/21		333.63KB	Share
OPT Ceasing to be a substantial holder
24/09/21		82.28KB	Share
OPT Becoming a substantial holder
21/09/21		204.37KB	Share
OPT Addendum to Notice of Meeting
21/09/21		273.88KB	Share
OPT Ceasing to be a substantial holder
16/09/21		90.09KB	Share
OPT Notice of Annual General Meeting and Proxy Form
14/09/21		591.18KB	Share
OPT Opthea Appendix 4G Corporate Governance Statement amended
06/09/21		625.05KB	Share
OPT Opthea to present at September Investor Conferences
03/09/21		126.83KB	Share
OPT Opthea Appendix 4G Corporate Governance Statement
30/08/21		693.95KB	Share
OPT Opthea reports Fiscal Year 2021 Results and Highlights
30/08/21	PRICE SENSITIVE	147.59KB	Share
OPT Opthea Appendix 4E and Annual Report
30/08/21	PRICE SENSITIVE	2.17MB	Share
OPT Becoming a substantial holder
27/08/21		866.02KB	Share
OPT Becoming a substantial holder
25/08/21		195.5KB	Share
OPT Ceasing to be a substantial holder
25/08/21		199.41KB	Share
OPT Ceasing to be a substantial holder
24/08/21		115.04KB	Share
OPT Becoming a substantial holder
24/08/21		813.37KB	Share
OPT Ceasing to be a substantial holder
19/08/21		218.2KB	Share
OPT Becoming a substantial holder
12/08/21		797.9KB	Share
OPT Opthea to present at H.C Wainwright Ophthalmology Conference
11/08/21		124.83KB	Share
OPT Opthea expands Phase 3 for OPT-302 into Canada
10/08/21		184.91KB	Share
OPT Ceasing to be a substantial holder
03/08/21		402.32KB	Share
OPT Opthea's OPT-302 Granted Fast-Track for wet AMD
06/07/21	PRICE SENSITIVE	166.94KB	Share
OPT Change in substantial holding
23/06/21		590.1KB	Share
OPT Change in substantial holding
22/06/21		90.51KB	Share
OPT Cleansing Notice
22/06/21		235.42KB	Share
OPT Application for quotation of securities - OPT
22/06/21		24.64KB	Share
OPT Change in substantial holding
22/06/21		868.53KB	Share
OPT Change in substantial holding
21/06/21		311.77KB	Share
OPT Proposed issue of securities - OPT
21/06/21		24.29KB	Share
OPT Opthea Appoints Company Secretary and VP of Finance
15/06/21		83.57KB	Share
OPT Initial Director's Interest Notice-JH
07/06/21		201.33KB	Share
OPT Initial Director's Interest Notice-JR
07/06/21		201.39KB	Share
OPT Director Appointment/Resignation
02/06/21		205.32KB	Share
OPT Change in substantial holding
25/05/21		792.07KB	Share
OPT Becoming a substantial holder
28/04/21		202.59KB	Share
OPT Opthea Company Secretary Resignation
06/04/21		85.84KB	Share
OPT Opthea Receives FDA Waiver for Pediatric Study Plan
31/03/21	PRICE SENSITIVE	159.31KB	Share
OPT Change in substantial holding
26/03/21		1.09MB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 60.0¢		Change 0.000(0.00%)		Mkt cap ! $820.7M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

OPT (ASX) Chart

Day chart unavailable

OPTHEA LIMITED - Announcements

Announcements

Top Stories